Navigation Links
BioCryst Updates Peramivir Clinical Development Plan
Date:1/23/2008

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )

Following release of preliminary Phase II results in September 2007, the Company completed additional analyses of the clinical data and performed a preliminary analysis of the virologic data from this trial. The Company also conducted further pharmacokinetic (PK) studies in healthy volunteers and has had discussions with the FDA and The Department of Health and Human Services (HHS) in support of the continuing development of peramivir.

Preliminary analysis of the virologic data from the Phase II trial indicated that i.m. peramivir demonstrated statistically significant reductions in influenza virus shedding in both active treatment groups when compared to placebo, with greater reductions in the 300mg group (p<0.001). Additionally, pharmacokinetic studies have been completed that indicate that needle length impacts adequate and consistent systemic exposure to i.m. peramivir. These PK studies also provide guidance on the appropriate needle length to use in future studies to provide adequate drug exposure for subjects based upon an individual's body mass index (BMI) and gender.

Based on these clinical results and virologic data, the Company believes that a single i.m. dose of 300mg peramivir can be a potentially clinically effective dose. Given the dose-response observed between the
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... 18, 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today announced ... full-year ended June 30, 2014. Quarter ... ended June 30, 2014 increased $492,000, or 18%, to ... ended June 30, 2013, due primarily to an increase ... from the Company,s largest customer, partially offset by an ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "China PTCA Balloon Market Investment Report, 2014-2016" ... balloon, as a indispensable medical device in percutaneous coronary ... for stent, but also as a device for pre-/post-stent ... closely related to that of PCI. As ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/19/2014)... also known as Johne,s disease, is caused by ... (MAP). In Austria, there is a legal obligation ... and causes treatment-resistant diarrhoea and wasting among affected ... for commercial farms. The animals produce less milk, ... other conditions such as udder inflammation. , ...
(Date:9/19/2014)... 19, 2014 The Canton Group, Baltimore’s leading ... website for the Xaverian Brothers. The new site aligns ... encourage and edify one another through a life of Gospel ... summons “to manifest God’s care and compassionate love to the ... was developed using a responsive web design, which allows users ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has bagged a huge ... HR outsourcing services in India. , " Profit By RPO ... act as a talent acquisition and transformation partner. Under the ... 3 locations in India in the next four months," the ... win for us and we are delighted to collaborate with ...
(Date:9/19/2014)... The dentist at Encino Esthetic Dental ... Throughout the month of September, new patients will be able ... just $69. A complimentary home teeth whitening kit will be ... gums checked and meet the team at Encino Esthetic Dental ... protect oral health. According to the American Dental Association, biannual ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Women of ... to maintain better oral care and visit the dentist ... Centers for Disease Control and Prevention. Researchers found ... Mexican-American, as well as those with lower income and ... Oral disease, with symptoms such as cavities or ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Oral Health in Women of Childbearing Age Needs Improvement 2
... effects in patients with high-grade glioma from chemoradiation may ... radiation oncologists at the Kimmel Cancer Center at ... the April issue of the British Journal ... occurrence of early side effects, such as fatigue and ...
... prohibition against testosterone therapy in men with untreated or ... study published in The Journal of Urology . ... a history of prostate cancer, even if treated and ... to the belief that testosterone activated prostate cancer growth, ...
... secure emotional relationship with their parents, and particularly their mothers, ... , according to new research. The study suggests that ... have at least 30 percent higher odds for obesity by ... researchers accounted for other family-related factors that could provide alternative ...
... Dieters are so involved with trying to eat virtuously that they ... labeled as healthy, according to a new study in the ... names can work to their disadvantage. "Keeping your weight-loss goal ... you are careful to avoid pasta selections and instead order from ...
... INDIANAPOLIS Jason S. Meyer, Ph.D., assistant professor of ... University Indianapolis, will be honored by the largest eye ... which one day may lead to reversal of blindness ... of the retina. The Association for Research ...
... smoke a cigarette may not be enough to protect the ... to a new study in the American Journal of ... Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... recognized category of tobacco smokeknown as "thirdhand smoke"can have as ...
Cached Medicine News:Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study suggests another look at testosterone-prostate cancer link 2Health News:Study suggests another look at testosterone-prostate cancer link 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 2Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 4Health News:When a salad is not a salad: Why are dieters easily misled by food names? 2Health News:IUPUI faculty member to receive national innovative vision research award 2Health News:LA BioMed study finds 'thirdhand smoke' poses danger to unborn babies' lungs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: